Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy by Storey, Robert F. et al.
F
C
F
H
B
I
D
T
f
r
T
r
a
M
Journal of the American College of Cardiology Vol. 56, No. 18, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PInhibitory Effects of Ticagrelor
Compared With Clopidogrel on Platelet Function
in Patients With Acute Coronary Syndromes
The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
Robert F. Storey, MD, DM,* Dominick J. Angiolillo, MD, PHD,† Shankar B. Patil, MD,*
Bhaloo Desai, MD,† Rosemary Ecob, MA,* Steen Husted, MD, DSC,‡
Hakan Emanuelsson, MD, PHD,§ Christopher P. Cannon, MD, Richard C. Becker, MD,¶
Lars Wallentin, MD, PHD#
Sheffield, United Kingdom; Jacksonville, Florida; Århus, Denmark; Mölndal and Uppsala, Sweden;
Boston, Massachusetts; and Durham, North Carolina
Objectives The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet
effects of clopidogrel and ticagrelor in patients with acute coronary syndromes.
Background The PLATO study demonstrated superiority of ticagrelor over clopidogrel in the prevention of ischemic events in
patients with acute coronary syndromes.
Methods Patients were randomized to receive either clopidogrel (300- to 600-mg loading dose [LD], 75 mg/day) or ti-
cagrelor (180-mg LD, 90 mg twice daily). The effects of maintenance therapy were studied in 69 patients pre-
and 2 to 4 h post-dose after at least 28 days. The LD effect was studied in 24 clopidogrel-naive patients. Light
transmittance aggregometry (adenosine diphosphate 5 to 20 M), VerifyNow P2Y12, and VASP phosphorylation
assays were performed.
Results During maintenance therapy, ticagrelor achieved greater suppression of platelet reactivity compared with clopi-
dogrel. The mean maximum light transmittance aggregometry responses (adenosine diphosphate 20 M) post-
maintenance dose were 44  15% for clopidogrel and 28  10% for ticagrelor (p  0.001). High platelet reac-
tivity was seen more frequently in the clopidogrel group. Proton pump inhibitor use was associated with higher
platelet reactivity with clopidogrel but not ticagrelor. The ticagrelor LD also achieved greater inhibition of platelet
aggregation compared with the clopidogrel LD.
Conclusions Ticagrelor achieves greater antiplatelet effect than clopidogrel in patients with acute coronary syndromes, both
in the first hours of treatment and during maintenance therapy. (J Am Coll Cardiol 2010;56:1456–62) © 2010
by the American College of Cardiology Foundation
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October 26, 2010:1456–62 Platelet Inhibitory Effects of Ticagreloricagrelor, an oral, reversibly binding platelet P2Y12 recep-
or inhibitor, yields greater inhibition of platelet aggregation
IPA) than clopidogrel (1,2). The inhibitory effects of
lopidogrel are predominantly determined by platelet expo-
ure to its active metabolite, which varies widely among
ndividuals as a consequence of drugs such as proton pump
nhibitors and genetic and other factors (3). The inhibitory
ffects of ticagrelor predominantly reflect the plasma levels
f ticagrelor; consequently its onset of action is faster and its
nhibitory effects more pronounced and predictable than
hose of clopidogrel (1,2).
In the PLATO (PLATelet inhibition and patient Out-
omes) study, ticagrelor reduced the incidence of the
rimary end point of cardiovascular death, myocardial
nfarction, and stroke compared with clopidogrel (4). The
LATO PLATELET substudy was conducted to further
haracterize the effects of ticagrelor compared with clo-
emographic Characteristics, Recorded atandomization, and Comedication at the Time oflood S mpli g After >28 Days of Stu y Drug
Table 1
Demographic Ch racteris ics, Rec rded at
Randomization, and Comedication at the Time of
Blood Sampling After >28 Days of Study Drug
Clopidogrel
(n  32)
Ticagrelor
(n  37) p Value
Age, yrs 63 61 0.41
Female sex 5 (16) 8 (22) 0.55
Median body weight, kg 84 (58–112) 76 (42–119) 0.29
Body mass index, kg/m2 28 (23–36) 27 (12–42) 0.66
Body mass index, kg/m2 628 628
Race
White 29 (91) 33 (89) 1.00
Black 2 (6) 1 (3) 0.59
Asian 0 (0) 2 (5) 0.49
Oriental 1 (3) 0 (0) 0.46
Other 0 (0) 1 (3) 1.00
Diagnosis
STEMI 12 (38) 14 (38) 1.00
NSTEMI 20 (63) 20 (54) 0.62
Unstable angina 0 (0) 3 (8) 0.24
Cardiovascular risk factors
Habitual smoker 7 (22) 14 (38) 0.19
Diabetes mellitus 8 (25) 5 (14) 0.35
Duration of treatment with study
medication, days
160 129 201 134 0.21
Concomitant medications
Aspirin 31 (97) 35 (95) 1.00
Mean dose (mg) 108 98
75–81 mg/day 27 (84) 31 (84)
150–162.5 mg/day 0 (0) 1 (3)
300–325 mg/day 4 (13) 3 (8)
Beta-blockers 29 (91) 28 (76) 0.12
ACE inhibitors 26 (81) 32 (87) 0.74
Calcium-channel blockers 6 (19) 4 (11) 0.49
Statins 31 (97) 36 (97) 1.00
Proton pump inhibitors 13 (41) 12 (32) 0.46
Nitrates 22 (69) 27 (73) 0.79
alues are mean, n (%), median (range), or mean  SD. p values determined by the Fisher exact
est for proportions or unpaired t test for continuous variables.
ACE  angiotensin-converting enzyme; NSTEMI  non–ST-segment elevation myocardial infarc-
ion; STEMI  ST-segment elevation myocardial infarction.
Vidogrel in patients with acute
oronary syndromes (ACS).
ethods
tudy design. The inclusion
riteria for this substudy were
he same as for the main PLATO
tudy (4). Two cohorts of patients
ere studied: patients who had
eceived study medication for at
east 28 days and patients who had
ot received treatment with clopi-
ogrel within the past 14 days and
ad not yet received study medica-
ion. Venous blood samples were
ollected by venipuncture into citrated tubes at time points
ndicated in the Results section. Further details of the study
esign and other supplementary information are provided in
he Online Appendix.
latelet aggregation studies. Light transmittance aggre-
ometry (LTA) was performed at all time points using
denosine diphosphate (ADP) (5 and 20 M) as agonist
emographic Characteristics and Comedicationt Time of Loading Dose AdministrationTable 2 Demograph c Charac eristics and Comedicationat Time of Loading Dose Administration
Clopidogrel
(n  12)
Ticagrelor
(n  12) p Value
Age, yrs 66 65 0.86
Female sex 1 (8) 1 (8) 1.00
Median body weight, kg 84 (63–112) 72 (67–117) 0.44
Body mass index, kg/m2 27 (21–35) 25 (18–42) 0.55
Body mass index, kg/m2 27 26
Race
White 11 (92) 11 (92) 1.00
Black 0 (0) 1 (8) 1.00
Asian 0 (0) 0 (0) 1.00
Oriental 1 (8) 0 (0) 0.47
Other 0 (0) 0 (0) 1.00
Diagnosis
STEMI 5 (42) 5 (42) 1.00
NSTEMI 7 (58) 6 (50) 1.00
Unstable angina 0 (0) 1 (8) 1.00
Cardiovascular risk factors
Habitual smoker 2 (17) 5 (42) 0.37
Diabetes mellitus 2 (17) 2 (17) 1.00
Concomitant medications
Aspirin 11 (92) 12 (100) 0.47
Mean aspirin dose, mg 293 306
Beta-blockers 3 (25) 2 (17) 1.00
ACE inhibitors 5 (42) 2 (17) 0.37
Calcium-channel blockers 2 (17) 0 (0) 0.47
Statins 2 (17) 3 (25) 0.59
Proton pump inhibitors 3 (25) 2 (17) 1.00
Nitrates 3 (25) 5 (42) 0.66
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
IPA  inhibition of platelet
aggregation
LD  loading dose
LTA  light transmittance
aggregometry
PRI  platelet reactivity
index
VASP  vasodilator-
stimulated phosphoproteinalues are mean, n (%), or median (range). p values deter
Abbreviations as in Table 1.mined by the Fisher exact test.
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esponse after 6 min were recorded. The proportions of
atients in each group with responses associated with
ncreased risk of ischemic events were determined according
o the following thresholds: maximum response to ADP
0M50% (5) and final response to ADP 5M14% (6).
erifyNow P2Y12 assay. Venous blood was collected
nto a 2-ml citrate Vacutainer and analyzed using the
Figure 1 Responses to Maintenance Doses of Clopidogrel and
Effects of clopidogrel (C) 75 mg/day (n  32) or ticagrelor (T) 90 mg twice daily (n
maintenance dose assessed by light transmittance aggregometry (LTA) showing m
(ADP 20 M) (B), maximum LTA response (ADP 5 M) (C), final LTA response (ADP 5
*p  0.01; **p  0.001.erifyNow P2Y12 system (Accumetrics Inc., San Diego,
alifornia) according to the manufacturer’s instructions.
latelet reaction units and the thrombin receptor activat-
ng peptide–induced response were recorded. The pro-
ortion of patients in each treatment group with re-
ponses 235 platelet reaction units was determined
ecause this threshold has been previously associated
ith increased ischemic risk (7).
relor
) on individual platelet function responses pre- (trough) and 2 to 4 h post- (peak)
LTA response (adenosine diphosphate [ADP] 20 M) (A), final LTA response
D), VerifyNow P2Y12 (E), and vasodilator-stimulated phosphoprotein assay (F).Ticag
 37
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October 26, 2010:1456–62 Platelet Inhibitory Effects of Ticagrelorasodilator-stimulated phosphoprotein (VASP) assay.
liquots of whole blood were processed using a VASP
hosphorylation assay kit, and the platelet reactivity index
PRI) was determined according to the manufacturer’s
nstructions (BioCytex, Marseille, France).The proportions
f patients in each treatment group with PRI 50% were
etermined because this threshold has been associated with
ncreased ischemic risk (8).
tatistical analysis. Data were analyzed using SPSS ver-
ion 15.0 (SPSS Inc., Chicago, Illinois), and expressed as
ean and SD. Clopidogrel and ticagrelor group continuous
ata were compared using either an unpaired t test for
arametric data or the Mann-Whitney test for data with
ignificantly different variances determined by the Levene test.
ategorical variables were compared using the Fisher exact
est. Statistical significance was attached to p values 0.01 to
llow for multiple group comparisons.
esults
tudy population. Sixty-nine patients were studied after at
east 28 days of maintenance treatment with either clopi-
ogrel 75 mg/day (n  32) or ticagrelor 90 mg twice daily
n  37). Twenty-four clopidogrel-naive patients were
nrolled and received either a clopidogrel LD of 300 mg
n  7) or 600 mg (n  5) or a ticagrelor LD of 180 mg
n  12). Demographic characteristics and comedication
ere well matched in both cohorts (Tables 1 and 2).
ffects of clopidogrel and ticagrelor maintenance regimens.
TA responses were lower in the ticagrelor group compared
ith the clopidogrel group, both before the next mainte-
ance dose (trough) and 2 to 4 h post-dose (peak) (Figs. 1A
o 1D). VerifyNow P2Y12 measurements were also lower in
he ticagrelor group compared with the clopidogrel group at
oth trough and peak, and there was remarkable consistency
f response in the ticagrelor group at peak (Fig. 1E). PRI
evels were lower at both peak and trough in the ticagrelor
roup compared with the clopidogrel group (Fig. 1F).
omparison of the ticagrelor and clopidogrel groups ac-
ording to geographic location in the United Kingdom or
nited States showed similar patterns of responses (Fig. 2).
ffects of clopidogrel and ticagrelor LDs. Clopidogrel
chieved overall moderate inhibition of platelet aggrega-
ion induced by ADP 20 M, with marked interindi-
idual variation, whereas ticagrelor achieved marked
nhibition by 1 h post-dose in all except 1 patient (for
hom a 2-h sample was not obtained); in the latter
atient, who presented with an inferior ST-segment
levation myocardial infarction, onset of effect was de-
ayed until 4 to 8 h post-dose (Figs. 3A and 3B). Platelet
ggregation induced by ADP 5 M was more sensitive to
nhibition by clopidogrel (Figs. 3C and 3D).
VerifyNow assay showed greater inhibitory effects of
icagrelor at 4 h compared with clopidogrel, whereas the
ASP data at 4 h only showed a nonsignificant trend (p 
.028) (Figs. 3E and 3F). sesponse to study therapy according to thresholds of
schemic risk. During maintenance treatment, all measures
howed almost no poor responders in the ticagrelor group,
hereas this was fairly common in the clopidogrel group
oth at trough and peak (Table 3).
roton pump inhibitors and platelet reactivity. During
aintenance therapy, patients treated with both clopidogrel
nd a proton pump inhibitor had greater platelet aggrega-
ion values than clopidogrel-treated patients not receiving a
roton pump inhibitor (Table 4). There was no difference in
latelet reactivity between ticagrelor-treated patients receiv-
ng or not receiving this comedication.
PA. IPA was determined for the 24 clopidogrel-naive
atients using LTA results with ADP 20 M (Figs. 4A
nd 4B).
iscussion
his PLATO substudy is the largest assessment to date of
latelet reactivity in the maintenance phase of treatment of
CS patients with ticagrelor and incorporated additional
ethods of assessing P2Y12 inhibition compared with our
revious assessment with LTA alone (1). All the platelet
unction measurements show greater levels of inhibition
ith ticagrelor compared with clopidogrel, and the discrim-
nation between the 2 treatment groups with the VerifyNow
2Y12 system is striking.
The PLATO PLATELET substudy also demonstrates
hat ticagrelor has a more rapid onset of action than
lopidogrel when administered to patients with ACS,
einforcing data from previous studies (1,2). The majority
f patients treated with ticagrelor in this acute setting
Figure 2 VerifyNow Responses
According to Geographic Location
Effects of clopidogrel (C) 75 mg/day or ticagrelor (T) 90 mg twice daily on indi-
vidual platelet function responses at trough and peak assessed by VerifyNow
P2Y12 according to geographic location in United Kingdom (C: n  23;
T: n  26) or U.S. (C: n  9;T: n  11). All p  NS.howed marked IPA at 1 h post-LD compared with a
r
m
a
r
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Platelet Inhibitory Effects of Ticagrelor October 26, 2010:1456–62elatively slow onset of action of the clopidogrel LD,
irroring recent findings in patients with stable coronary
Figure 3 Responses to Loading Doses of Clopidogrel and Ticag
Effects of clopidogrel (C) 300 to 600 mg (n  12) or ticagrelor (T) 180 mg (n  1
1, 2, 4, 8, and 12 h post-dose) showing maximum LTA response (ADP 20 M) (A)
LTA response (ADP 5 M) (D), VerifyNow P2Y12 (E), and vasodilator-stimulated ph
Abbreviations as in Figures 1 and 2.rtery disease (2). iOur analysis of the proportions of patients with platelet
eactivity above thresholds associated with increased risk of
ndividual platelet function responses assessed by LTA (pre-dose and
LTA response (ADP 20 M) (B), maximum LTA response (ADP 5 M (C), final
protein assay (pre-dose and 4 h only) (F). *p  0.01; **p  0.001.relor
2) on i
, final
osphoschemic events showed that there were fewer patients with
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October 26, 2010:1456–62 Platelet Inhibitory Effects of Ticagrelorigh platelet reactivity in the ticagrelor group compared
ith the clopidogrel group, during both maintenance treat-
ent and after LD administration. A PRU level 235 has
reviously been shown to be associated with an increased
isk of stent thrombosis (7), and only 1 of the ticagrelor-
reated patients had a level greater than this at trough during
aintenance treatment, with all the ticagrelor-treated pa-
roportions of Platelet Function Responseseater Than Risk Thresholds for Ischemic EventsTable 3 Proportions of Platelet Function ResponsesGreater Than Risk Thresholds for Ischemic Events
No. Above Threshold/Total n (%) Clopidogrel Ticagrelor p Value
Maximum LTA response to ADP 20 M 50%
Pre-MD 18/31 (58) 3/35 (9) 0.0001
2–4 h post-MD 13/31 (42) 1/37 (3) 0.0001
1 h post-LD 5/8 (63) 1/11 (9) 0.04
2 h post-LD 6/9 (67) 1/8 (13) 0.05
4 h post-LD 5/8 (63) 1/10 (10) 0.04
8 h post-LD 6/9 (67) 1/10 (10) 0.02
12 h post-LD 4/8 (50) 0/10 (0) 0.02
Final LTA response to ADP 5 M 14%
Pre-MD 15/31 (48) 4/34 (12) 0.02
2–4 h post-MD 7/31 (23) 0/36 (0) 0.01
1 h post-LD 5/8 (63) 2/11 (18) 0.07
2 h post-LD 4/9 (44) 0/8 (0) 0.08
4 h post-LD 2/8 (25) 1/10 (10) 0.56
8 h post-LD 4/9 (44) 1/10 (10) 0.14
12 h post-LD 4/9 (44) 1/9 (11) 0.29
VerifyNow P2Y12 235 PRUs
Pre-MD 13/29 (45) 1/34 (3) 0.0001
2–4 h post-MD 12/31 (39) 0/36 (0) 0.0001
4 h post-LD 6/9 (67) 1/8 (13) 0.05
VASP PRI 50%
Pre-MD 17/25 (68) 3/34 (9) 0.0001
2-4 h post MD 13/25 (52) 1/33 (3) 0.0001
4 h post-LD 4/7 (57) 3/11 (27) 0.33
values derived by the Fisher exact test.
ADP  adenosine diphosphate; LD  loading dose; LTA  light transmittance aggregometry;
D  maintenance dose; PRI  platelet reactivity index; PRUs  platelet reaction units; VASP 
asodilator-stimulated phosphoprotein.
Platelet Function Responses During MaintenancAccording to Treatment With PPIsTable 4 Platelet Funct on Re ponses Duri gAccording to Treatment With PPIs
Clopid
PPI
(n  13)
Maximum LTA response to ADP 20 M, %
Pre-MD 56 10
2–4 h post-MD 55 15
Final LTA response to ADP 5 M, %
Pre-MD 25 21
2–4 h post-MD 23 22
VerifyNow P2Y12, PRUs
Pre-MD 262 76
2–4 h post-MD 247 99
VASP PRI, %
Pre-MD 59 18
2–4 h post-MD 58 20p values derived by unpaired Student t test.
PPI  proton pump inhibitor; other abbreviations as in Table 3.ients having levels less than this at peak, compared with
5% and 39% of the clopidogrel-treated patients at trough
nd peak, respectively (both p  0.001). Similarly, a PRI
alue greater than approximately 50% in clopidogrel-treated
CI patients has been associated with an increased risk of
tent thrombosis (8), and only 1 patient (3%) in the
icagrelor group had a PRI level 50% at peak compared
ith 13 patients (52%) in the clopidogrel group (p 0.001).
onsistent with other studies, we found that platelet reac-
ivity was higher in clopidogrel-treated patients receiving
roton pump inhibitors compared with those not receiving
roton pump inhibitors. Numerous confounding variables
ay influence platelet reactivity differentially in the 2
onrandomized groups other than an interaction between
roton pump inhibitors and clopidogrel. However, the
nding that there was no apparent effect of proton pump
nhibitors on the response to ticagrelor provides reassurance
bout the appropriateness of coprescribing ticagrelor and
roton pump inhibitors.
tudy limitations. There were insufficient numbers of
lopidogrel-naive patients receiving the standard and double
D of clopidogrel to compare each separately with the
icagrelor LD. There were insufficient numbers in the
aintenance phase to analyze completely the effects of
otential drug interactions on response to clopidogrel.
harmacokinetic samples were not collected simultaneously
o the samples for platelet function analysis to allow assess-
ent of relationships between the two. This substudy was
ot powered to assess the relationship between pharmaco-
ynamic data and clinical outcomes.
onclusions
icagrelor demonstrates a greater platelet inhibitory effect
han clopidogrel in ACS patients both during maintenance
herapy and in the first hours of treatment. These effects
erapyntenance Therapy
p Value
Ticagrelor
p Value
PPI
19)
PPI
(n  12)
No PPI
(n  25)
 15 0.04 37 14 35 14 0.59
 15 0.007 29 12 27 9 0.68
 11 0.054 9 9 5 8 0.21
 8 0.013 3 3 2 4 0.73
 64 0.005 92 116 74 61 0.56
 70 0.005 32 29 31 34 0.98
 25 0.47 31 19 25 20 0.43
 24 0.23 18 11 13 13 0.32e ThMai
ogrel
No
(n 
45
39
13
7
181
151
53
47
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icagrelor compared with clopidogrel.
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